Literature DB >> 18066656

The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.

Suleyman Serdar Koca1, Ibrahim Halil Bahcecioglu, Orhan Kursat Poyrazoglu, Ibrahim Hanifi Ozercan, Kazim Sahin, Bilal Ustundag.   

Abstract

To assess the effects of anti-TNF-alpha antibody (infliximab) in experimental steatohepatitis induced by methionine- and choline-deficient (MCD) diet. The study included thirty rats. One group received normal rat food, and two groups received MCD diet. The treatment group received a single dose intra-peritoneal infliximab (4 mg/kg), at week 8. MCD diet increased levels of AST, ALT, TNF-alpha, TGF-beta(1), tissue and plasma MDA (p < 0.05 for each). Moreover, it led to steatosis, ballooning degeneration, inflammation, fibrosis and increased actin expression, histopathologically (p < 0.05 for each). In this experimental steatohepatitis anti-TNF-alpha antibody decreased the levels of AST, ALT, TGF-beta(1) and plasma and tissue MDA (p < 0.05 for each). Moreover, inflammation, necrosis, actin expression and fibrosis decreased in anti-TNF-alpha group compared to placebo group (p < 0.05 for each). This study indicates that anti-TNF-alpha antibody is effective on necrosis, inflammation and fibrosis in the experimental model of non-alcoholic steatohepatitis, induced by MCD diet.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066656     DOI: 10.1007/s10753-007-9053-z

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.657


  35 in total

1.  Steatohepatitis: a tale of two "hits"?

Authors:  C P Day; O F James
Journal:  Gastroenterology       Date:  1998-04       Impact factor: 22.682

2.  Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.

Authors:  H Ohkawa; N Ohishi; K Yagi
Journal:  Anal Biochem       Date:  1979-06       Impact factor: 3.365

3.  CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.

Authors:  I A Leclercq; G C Farrell; J Field; D R Bell; F J Gonzalez; G R Robertson
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.

Authors:  R M Strieter; D G Remick; P A Ward; R N Spengler; J P Lynch; J Larrick; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

5.  Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients.

Authors:  J Crespo; A Cayón; P Fernández-Gil; M Hernández-Guerra; M Mayorga; A Domínguez-Díez; J C Fernández-Escalante; F Pons-Romero
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

Review 6.  Clinical features and natural history of nonalcoholic steatosis syndromes.

Authors:  Y Falck-Ytter; Z M Younossi; G Marchesini; A J McCullough
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

7.  Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells.

Authors:  Xiao-Jing Liu; Li Yang; Yong-Qiu Mao; Qiong Wang; Ming-Hui Huang; Yi-Ping Wang; Hong-Bin Wu
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

8.  The involvement of Kupffer cells in carbon tetrachloride toxicity.

Authors:  M J Edwards; B J Keller; F C Kauffman; R G Thurman
Journal:  Toxicol Appl Pharmacol       Date:  1993-04       Impact factor: 4.219

9.  Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis.

Authors:  Sanjay K Satapathy; Sanjay Garg; Ranjeet Chauhan; Puja Sakhuja; Veena Malhotra; Barjesh C Sharma; Shiv K Sarin
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

10.  Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor.

Authors:  M J Czaja; J Xu; E Alt
Journal:  Gastroenterology       Date:  1995-06       Impact factor: 22.682

View more
  52 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.

Authors:  Rotonya M Carr; Arpan Patel; Hillary Bownik; Amanke Oranu; Caroline Kerner; Amy Praestgaard; Kimberly A Forde; K Rajender Reddy; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2017-03-06       Impact factor: 3.199

Review 3.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 4.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

5.  Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-a case series and review of the literature.

Authors:  Christopher E McGowan; Patricia Jones; Millie D Long; A Sidney Barritt
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

Review 6.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 7.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 8.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology.

Authors:  Guy Bower; Tania Toma; Leanne Harling; Long R Jiao; Evangelos Efthimiou; Ara Darzi; Thanos Athanasiou; Hutan Ashrafian
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

9.  Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.

Authors:  James P Luyendyk; Bradley P Sullivan; Grace L Guo; Ruipeng Wang
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

Review 10.  Choline's role in maintaining liver function: new evidence for epigenetic mechanisms.

Authors:  Mihai G Mehedint; Steven H Zeisel
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-05       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.